OBJECTIVE: The value of combined positron emission tomography (PET)/computed tomography (CT) in the follow-up of patients with breast cancer with elevated tumor markers but without proven metastases or local recurrence was assessed. METHODS: Thirty-four women underwent PET/CT. The PET and CT images were first analyzed separately; fused findings were then interpreted, blinded to the results of the other modalities. The results of CT, PET, and PET/CT were compared with each other and correlated to the final diagnosis. RESULTS: The PET/CT identified 149 malignant foci in 24 patients (71%). The CT detected 96 of these foci in 18 patients, whereas PET identified 124 foci in 17 patients. Differences between CT and PET were not significant. Differences between PET/CT and CT (P < 0.01) and PET/CT and PET (P < 0.01) were significant. The person-based sensitivity of PET/CT, PET, and CT was 96%, 88% and 96%, respectively. Specificity of PET/CT, PET, and CT was 89%, 78%, and 78%, respectively. CONCLUSIONS: The PET/CT is a valuable modality for the follow-up of patients with breast cancer and elevated levels of tumor markers.
OBJECTIVE: The value of combined positron emission tomography (PET)/computed tomography (CT) in the follow-up of patients with breast cancer with elevated tumor markers but without proven metastases or local recurrence was assessed. METHODS: Thirty-four women underwent PET/CT. The PET and CT images were first analyzed separately; fused findings were then interpreted, blinded to the results of the other modalities. The results of CT, PET, and PET/CT were compared with each other and correlated to the final diagnosis. RESULTS: The PET/CT identified 149 malignant foci in 24 patients (71%). The CT detected 96 of these foci in 18 patients, whereas PET identified 124 foci in 17 patients. Differences between CT and PET were not significant. Differences between PET/CT and CT (P < 0.01) and PET/CT and PET (P < 0.01) were significant. The person-based sensitivity of PET/CT, PET, and CT was 96%, 88% and 96%, respectively. Specificity of PET/CT, PET, and CT was 89%, 78%, and 78%, respectively. CONCLUSIONS: The PET/CT is a valuable modality for the follow-up of patients with breast cancer and elevated levels of tumor markers.
Authors: Erika J Schneble; Lindsey J Graham; Matthew P Shupe; Frederick L Flynt; Kevin P Banks; Aaron D Kirkpatrick; Aviram Nissan; Leonard Henry; Alexander Stojadinovic; Nathan M Shumway; Itzhak Avital; George E Peoples; Robert F Setlik Journal: J Cancer Date: 2014-03-16 Impact factor: 4.207